Correction to: Isatuximab: First Approval.

abstract：:67 samples of 15 different tissues were obtained from 26 patients who were given an intravenous bolus dose of temocillin approximately 3 to 4 hours prior to surgery. 50 tissue samples were obtained from 19 patients who received 1g temocillin and 17 tissue samples were obtained from 7 patients who received 2g temocilli...

journal_title：Drugs

authors： Gould JG,Meikle G,Cooper DL,Horton R

更新日期：1985-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease that ultimately leads to disability and functional decline. Because patients usually develop RA in mid-life, they may experience its consequences for 20-30 years or longer. Proinflammatory cytokines, notably interleukin (IL)-1 and tumour necro...

journal_title：Drugs

authors： Schiff MH

更新日期：2004-01-01 00:00:00

abstract：:Rapid progress has recently been encountered in pharmacologically treating the unborn baby. This unique area of drug therapy raises new methodological and ethical questions. This article is a systematic review of known modalities of fetal pharmacotherapy, and aims to highlight essential principles, difficulties and co...

journal_title：Drugs

authors： Koren G,Klinger G,Ohlsson A

更新日期：2002-01-01 00:00:00

abstract：:Treatment of idiopathic membranous nephropathy is based on a 'symptomatic' therapy that includes ACE inhibitors or angiotensin II receptor antagonists, and on an 'aetiological' therapy aimed at modulating underlying immunological mechanisms. The role of the latter is still debated given the usually indolent course of ...

journal_title：Drugs

authors： Quaglia M,Stratta P

更新日期：2009-07-09 00:00:00

abstract：:Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity excee...

journal_title：Drugs

authors： Blair HA,Keating GM

更新日期：2016-03-01 00:00:00

abstract：:Patient compliance refers to the willingness and ability of an individual to follow health-related advice, to take medication as prescribed, to attend scheduled clinic appointments and to complete recommended investigations. It is a major health issue, with outcomes related to levels of morbidity, mortality and cost u...

journal_title：Drugs

authors： Murphy J,Coster G

更新日期：1997-12-01 00:00:00

abstract：:Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...

journal_title：Drugs

authors： Deeks ED,Lamb YN

更新日期：2020-04-01 00:00:00

abstract：:Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...

journal_title：Drugs

authors： Johnson MR,Lydiard RB,Ballenger JC

更新日期：1995-03-01 00:00:00

abstract：:Gene rearrangements involving the neurotrophic receptor kinase genes NTRK1, NTRK2, and NTRK3 (referred to as TRK, encoding TRKA, TRKB, and TRKC, respectively) result in highly oncogenic fusions. TRK fusions are rare, with a prevalence of < 1% in solid tumors. Detection of TRK fusions can be based on fluorescence in-si...

journal_title：Drugs

authors： Rohrberg KS,Lassen U

更新日期：2021-01-05 00:00:00

abstract：:The effect of cefotaxime and ceftriaxone on faecal flora was investigated in women undergoing routine vaginal or abdominal hysterectomy. Three groups of 9 patients received, in a double-blind fashion and just before surgery, cefotaxime 2g intravenously, ceftriaxone 2g intravenously or no antibiotic (controls). Stools ...

journal_title：Drugs

authors： Michéa-Hamzehpour M,Auckenthaler R,Kunz J,Pechère JC

更新日期：1988-01-01 00:00:00

abstract：:Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity, registration trials of immunotherapy in prostate cancer have largely been unsuccessful. Sipuleucel-T remains the only approved immunotherapy for the treatment of asymptomatic or m...

journal_title：Drugs

authors： Rathi N,McFarland TR,Nussenzveig R,Agarwal N,Swami U

更新日期：2020-12-28 00:00:00

abstract：:This review will discuss the safety profiles of the angiotensin-converting enzyme (ACE) inhibitors captopril, enalapril and lisinopril in patients with hypertension. In general, the safety profiles of ACE inhibitors compare favourably with those of other agents used for the treatment of hypertension. Adverse effects a...

journal_title：Drugs

authors： Warner NJ,Rush JE

更新日期：1988-01-01 00:00:00

abstract：:Bevacizumab is a recombinant, humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody that neutralizes the biological activity of VEGF and inhibits tumour angiogenesis. In two pivotal, well designed, phase III, clinical trials (GOG-0218 and ICON7) in women with advanced epithelial ovarian, fallopi...

journal_title：Drugs

authors： Dhillon S

更新日期：2012-05-07 00:00:00

abstract：:Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

journal_title：Drugs

authors： Markham A,Brogden RN

更新日期：1995-06-01 00:00:00

abstract：:Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

journal_title：Drugs

authors： Syed YY

更新日期：2021-01-01 00:00:00

abstract：:During the intervening years since metoprolol was first reviewed in the Journal (1977), it has become widely used in the treatment of mild to moderate hypertension and angina pectoris. Although much data have accumulated, its precise mechanisms of action in these diseases remain largely uncertain. Optimum treatment of...

journal_title：Drugs

authors： Benfield P,Clissold SP,Brogden RN

更新日期：1986-05-01 00:00:00

abstract：:Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

journal_title：Drugs

authors： Keam SJ,Croom KF,Keating GM

更新日期：2005-01-01 00:00:00

abstract：:Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...

journal_title：Drugs

authors： Robinson DM,Scott LJ,Plosker GL

更新日期：2006-01-01 00:00:00

abstract：:It is well documented that long term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of peptic ulcer and that gastroduodenal mucosal erosions can be demonstrated in volunteers within 1 week of treatment initiation. However, long term studies in nonsurgical patients have not documented g...

journal_title：Drugs

authors： Kehlet H,Dahl JB

更新日期：1992-01-01 00:00:00

abstract：:Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

journal_title：Drugs

authors： Scott LJ,Keam SJ

更新日期：2021-01-06 00:00:00

abstract：:A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...

journal_title：Drugs

authors： Grassi C,Gialdroni Grassi G,Mangiarotti P

更新日期：1987-01-01 00:00:00

abstract：:Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

journal_title：Drugs

authors： Berk M,Segal J,Janet L,Vorster M

更新日期：2001-01-01 00:00:00

abstract：:Patients with viral infections of the central nervous system (CNS) may present with a variety of neurological symptoms, most commonly dominated by either encephalitis or meningitis. The aetiological panorama varies in different parts of the world as well as over time. Thus, virological first-line diagnostics must be a...

journal_title：Drugs

authors： Studahl M,Lindquist L,Eriksson BM,Günther G,Bengner M,Franzen-Röhl E,Fohlman J,Bergström T,Aurelius E

更新日期：2013-02-01 00:00:00

abstract：:The most important aspect of modern management of acute diarrhoeal illness in children is that of oral rehydration therapy, and drug therapy is very rarely indicated. Despite the dramatic decline in mortality and morbidity in recent years, there is still the need for continuing education in the appropriate use of oral...

journal_title：Drugs

authors： Davies A,Jenkins HR

更新日期：1992-07-01 00:00:00

abstract：:Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...

journal_title：Drugs

authors： Kim ES

更新日期：2018-01-01 00:00:00

abstract：:It is important to distinguish between therapy used to reduce acute inflammation in gout and therapy used to manage hyperuricaemia in patients with chronic gouty arthritis. This article discusses treatments for acute gout, emphasizing the use of corticotrophin (adrenocorticotropic hormone; ACTH) and the evidence on wh...

journal_title：Drugs

authors： Schlesinger N

更新日期：2008-01-01 00:00:00

abstract：:The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

journal_title：Drugs

authors： Bailey RR

更新日期：1977-02-01 00:00:00

abstract：:The efficacy and safety of cefadroxil in the treatment of paediatric patients with a wide variety of infections were evaluated in a multicentre clinical trial. This study included 395 infants and children with Group A streptococcal pharyngitis, sinusitis, otitis media, bronchitis, pneumonia or bronchopneumonia, urinar...

journal_title：Drugs

authors： Puhakka H,Virolainen E

更新日期：1986-01-01 00:00:00

abstract：:This article is a review of the principal drug-induced psychiatric symptoms that are likely to be encountered in daily clinical practice as a result of drug abuse, overdoses or side effects of drugs prescribed for treatment. Many categories of medication have the potential to produce psychiatric symptoms, but antitube...

journal_title：Drugs

authors： Johnson DA

更新日期：1981-07-01 00:00:00

abstract：:Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...

journal_title：Drugs

authors： Keating GM,Jarvis B

更新日期：2001-01-01 00:00:00